Bevacizumab (B) (10 mg/kg) in combination with cisplatin (C) and docetaxel (D) administered every 2 weeks in patients (p) with advanced non-squamous non-Small Cell Lung Cancer (nsNSCLC): GGCP047/10 study
JOURNAL OF THORACIC ONCOLOGY（2013）
关键词
biweekly schedule,Bevacizumab,NSCLC
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要